阿仑膦酸钠和阿法骨化醇联合治疗严重骨质流失和骨质疏松性骨折

Alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures

背景:阿仑膦酸钠和阿法骨化醇均可抑制骨质疏松性骨折患者骨转换,增加骨矿物密度。目的:观察阿仑膦酸钠和阿法骨化醇联合治疗患有严重骨质流失和骨质疏松性骨折患者的效果。方法:纳入严重骨质流失和骨质疏松性骨折患者,进行阿仑膦酸钠和阿法骨化醇联合治疗2年。结果与结论:相比治疗前,阿仑膦酸钠和阿法骨化醇联合治疗后患者腰椎骨密度增加(P<0.05),随后尿Ⅰ型胶原N末端肽水平和血清碱性磷酸酶活性减少(P<0.05)。证实,阿仑膦酸钠和阿法骨化醇联合治疗患有严重的骨质流失和骨质疏松性骨折患者疗效好。

BACKGROUND： Alendronate and alfacalcidol can inhibit the bone transformation and increase bone mineral density of the patients with osteoporotic fractures. OBJECTIVE： To investigate the effect of alendronate plus alfacalcidol for the treatment of severe bone loss and osteoporotic fractures. METHODS： Patients with severe bone loss and osteoporotic fractures were selected, and then the patients were treated with alendronate plus alfacalcidol for 2 years. RESULTS AND CONCLUSION： Compared with before treatment, the lumbar spine bone density of the patients was increased after treated with alendronate plus alfacalcidol （P 0.05） followed by urine of type Ⅰ collagen N-terminal peptide levels and serum alkaline phosphatase activity decreased （P 0.05）. It confirmed that the alendronate plus alfacalcidol has good effect for the treatment of severe bone loss and osteoporotic fracture patients.